Point72 Europe (London) LLP Voyager Therapeutics, Inc. Transaction History
Point72 Europe (London) LLP
- $1.97 Billion
- Q3 2025
A detailed history of Point72 Europe (London) LLP transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 525 shares of VYGR stock, worth $2,100. This represents 0.0% of its overall portfolio holdings.
Number of Shares
525Holding current value
$2,100% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VYGR
# of Institutions
125Shares Held
29.9MCall Options Held
121KPut Options Held
16.2K-
Black Rock Inc. New York, NY5.31MShares$21.3 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.2MShares$16.8 Million0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.25MShares$13 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.29MShares$9.17 Million0.0% of portfolio
-
Vestal Point Capital, LP New York, NY1.48MShares$5.9 Million0.31% of portfolio
About Voyager Therapeutics, Inc.
- Ticker VYGR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,647,600
- Market Cap $155M
- Description
- Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...